Long-term efficacy data
(16 and 52 weeks)12-14
Strongly recommended by AAD and AAAAI guidelines as a systemic therapy for moderate-to-severe atopic dermatitis in adult patients1,2
How Adbry® Works
Adbry specifically targets and neutralizes IL-133,4
IL-13 Signaling
In atopic dermatitis, IL-13 signaling is a key driver of dysregulated immune response5
In chronic atopic dermatitis:
- IL-13 is overexpressed in both lesional and nonlesional skin6
- Overexpression of IL-13 contributes to the
vicious cycle of inflammation, microbiome dysbiosis,
pruritus, and skin-barrier dysfunction5,7
- Expression of IL-13 in skin correlates with increased disease severity6,8
Adbry—the first fully human, high-affinity monoclonal antibody that specifically targets IL-13 and leaves the natural function of the decoy receptor intact4,11
- Adbry is a fully human IgG4 monoclonal antibody that specifically binds to human IL-13, a naturally occurring cytokine of the type II immune response, and inhibits its interaction with the IL-13 receptor α1 and α2 subunits (IL-13Rα1 and IL-13Rα2).11
- Adbry selectively inhibits IL-13 interaction with the type II receptor complex (IL-13Rα1/IL-4Rα), preventing IL-13–induced inflammatory responses in the skin.11
Mechanism of Action
